Cytotoxic effect of thermosensitive magnetoliposomes loaded with gemcitabine and paclitaxel on human primary breast cancer cells (MGSO-3 line)

Ribeiro, Rita F.L.; Ferreira, Roberta Viana; Pedersoli, Davyston Carvalho; Paiva, Paulo Renato Perdigão; Cunha, Pricila da Silva; Góes, Alfredo M.; Domingues, Rosana Zacarias

doi:10.1007/s11051-020-04833-7

Cited by 14 publications

(7 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After incubation with MLPs, less than 10% of apoptotic cells were observed (Fig. 1 F), which aligns with previous reports on iron-based nanoparticles 31 , 56 , 57 .…”

Section: Discussionsupporting

confidence: 92%

Delivery and assessment of a CRISPR/nCas9-based genome editing system on in vitro models of mucopolysaccharidoses IVA assisted by magnetite-based nanoparticles

Leal

Cifuentes

Torres

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Mucopolysaccharidosis IV A (MPS IVA) is a lysosomal disorder caused by mutations in the GALNS gene. Consequently, the glycosaminoglycans (GAGs) keratan sulfate and chondroitin 6-sulfate accumulate in the lysosomal lumen. Although enzyme replacement therapy has shown essential advantages for the patients, several challenges remain to overcome, such as the limited impact on the bone lesion and recovery of oxidative profile. Recently, we validated a CRISPR/nCas9-based gene therapy with promising results in an in vitro MPS IVA model. In this study, we have expanded the use of this CRISPR/nCas9 system to several MPS IVA fibroblasts carrying different GALNS mutations. Considering the latent need to develop more safety vectors for gene therapy, we co-delivered the CRISPR/nCas9 system with a novel non-viral vector based on magnetoliposomes (MLPs). We found that the CRISPR/nCas9 treatment led to an increase in enzyme activity between 5 and 88% of wild-type levels, as well as a reduction in GAGs accumulation, lysosomal mass, and mitochondrial-dependent oxidative stress, in a mutation-dependent manner. Noteworthy, MLPs allowed to obtain similar results to those observed with the conventional transfection agent lipofectamine. Overall, these results confirmed the potential of CRISPR/nCas9 as a genome editing tool for treating MPS IVA. We also demonstrated the potential use of MLPs as a novel delivery system for CRISPR/nCas9-based therapies.

show abstract

“…After incubation with MLPs, less than 10% of apoptotic cells were observed (Fig. 1 F), which aligns with previous reports on iron-based nanoparticles 31 , 56 , 57 .…”

Section: Discussionsupporting

confidence: 92%

Delivery and assessment of a CRISPR/nCas9-based genome editing system on in vitro models of mucopolysaccharidoses IVA assisted by magnetite-based nanoparticles

Leal

Cifuentes

Torres

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Also, the size of PTX-PEG-ML NPs was significantly larger than that of PTX-PEG-L NPs (296.1±14 vs. 197.8±9 nm), indicating that MNPs were encapsulated into liposome NPs. Furthermore, the zeta potential of both PTX-PEG-L and PTX-PEG-ML NPs were negative, which was in agreement with the results of Ribeiro et al 47 and Toro-Cordova et al 48 studies as the magnetoliposome, synthesized in these studies, also had negative zeta potential (-8 ± 1 and -40.5 ± 0.8 mV in Ribeiro et al 47 and Toro-Cordova et al 48 studies, respectively). NPs with the same charge (positive or negative) have proper stability in aqueous solutions with low ionic strength as particles with the same net charge repulse each other, which, in turn, inhibits their aggregation.…”

Section: Discussionsupporting

confidence: 89%

“…The results demonstrated that PTX gemcitabine-loaded magnetoliposome caused higher cytotoxicity effects (by 27%) compared to PTX-gemcitabine-loaded liposome, after 48 h incubation. The higher potency of PTX-gemcitabine-loaded magnetoliposome compared to PTX-loaded magnetoliposome synthesized in the present study (27 vs. 12%) could be originated in the components used for synthesizing these formulations, the origin of the cells (e.g., ovarian vs. breast cancer), and the protocol used for the evaluation of the cytotoxicity effects (i.e., magnetoliposome for co-delivery of PTX and gemcitabine in Ribeiro et al 47 study vs. magnetoliposome for PTX delivery in the present study). Toro-Cordova et al, 48 in another study, synthesized cisplatin-loaded magnetoliposome and evaluated its cytotoxicity effects against human cervical cancer HeLa cells.…”

Section: Discussionmentioning

confidence: 78%

See 1 more Smart Citation

In vitro Assessment of Magnetic Liposomal Paclitaxel Nanoparticles as a Potential Carrier for the Treatment of Ovarian Cancer

et al. 2020

View full text Add to dashboard Cite

Purpose: This study aimed to evaluate the role of magnetic liposome nanoparticles (ML NPs) as a carrier for paclitaxel (PTX) for the treatment of ovarian cancer in vitro . Methods: Magnetic NPs (MNPs) were synthesized by chemical co-precipitation method. The resulting NPs were characterized in terms of size, size distribution, zeta potential, drug encapsulation efficiency (EE), drug release pattern, and cytotoxicity effects. Results: The size and zeta potential of PTX-PEG-L and PTX-PEG-ML NPs were determined to be 296, 198 nm; -20, and -19 mV, respectively. Also, their drug encapsulation efficiencies were determined to be 97% and 96%, respectively. It was found that PTX-PEG-ML NPs, compared to PTX-PEG-L NPs, caused a reduction (11%) in the rate of drug release. The cytotoxicity of the drug-loaded NPs was assessed using 3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay against human ovarian epithelial cancer (A2780CP) cells, and the results demonstrated that PTX-PEG-ML NPs caused higher cytotoxicity (by 14%) compared to PTX-PEG-L NPs (IC 50 : 1.88 ± 0.09 and 2.142 ± 0.1 µM, respectively). Conclusion: Overall, the results of this study suggest that PTX-PEG-ML NPs could be considered as a therapeutic candidate for the treatment of ovarian cancer.

show abstract

“…In this context, several surface modifications have been proposed to avoid MNPs aggregation and favor their biocompatibility [ 18 , 26 , 28 , 50 ]. Among them, lipid-based nanoparticles have been explored in the last years ( Table 1 ), such as liposomes, solid lipid nanoparticles, nanostructured lipid carriers, nanoemulsions, and microemulsions) [ 23 , 51 , 52 , 53 , 54 ]. These nanosystems are generally biocompatible, biodegradable, and able to encapsulate high amounts of hydrophobic drugs for cancer therapy [ 55 , 56 ].…”

Section: Magnetic Nanoparticles’ Properties and Applicationsmentioning

confidence: 99%

Hybrid Magnetic Lipid-Based Nanoparticles for Cancer Therapy

et al. 2023

View full text Add to dashboard Cite

Cancer is one of the major public health problems worldwide. Despite the advances in cancer therapy, it remains a challenge due to the low specificity of treatment and the development of multidrug resistance mechanisms. To overcome these drawbacks, several drug delivery nanosystems have been investigated, among them, magnetic nanoparticles (MNP), especially superparamagnetic iron oxide nanoparticles (SPION), which have been applied for treating cancer. MNPs have the ability to be guided to the tumor microenvironment through an external applied magnetic field. Furthermore, in the presence of an alternating magnetic field (AMF) this nanocarrier can transform electromagnetic energy in heat (above 42 °C) through Néel and Brown relaxation, which makes it applicable for hyperthermia treatment. However, the low chemical and physical stability of MNPs makes their coating necessary. Thus, lipid-based nanoparticles, especially liposomes, have been used to encapsulate MNPs to improve their stability and enable their use as a cancer treatment. This review addresses the main features that make MNPs applicable for treating cancer and the most recent research in the nanomedicine field using hybrid magnetic lipid-based nanoparticles for this purpose.

show abstract

Cytotoxic effect of thermosensitive magnetoliposomes loaded with gemcitabine and paclitaxel on human primary breast cancer cells (MGSO-3 line)

Cited by 14 publications

References 43 publications

Delivery and assessment of a CRISPR/nCas9-based genome editing system on in vitro models of mucopolysaccharidoses IVA assisted by magnetite-based nanoparticles

Delivery and assessment of a CRISPR/nCas9-based genome editing system on in vitro models of mucopolysaccharidoses IVA assisted by magnetite-based nanoparticles

In vitro Assessment of Magnetic Liposomal Paclitaxel Nanoparticles as a Potential Carrier for the Treatment of Ovarian Cancer

Hybrid Magnetic Lipid-Based Nanoparticles for Cancer Therapy

Contact Info

Product

Resources

About